Alembic Ltd

Alembic Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Ltd

₹ 87.1 1.30%
05 Jun - close price
alembiclimited.com BSE: 506235 NSE: ALEMBICLTD
About

Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.[1]

Key Points

Business Segments
A) Real Estate (~80% in FY24 vs 59% in FY22): [1] [2] The company is involved in the construction of residential & commercial real estate projects. It also leases commercial properties. [3] Real Estate business experienced strong growth between FY23-FY24 bolstered by strong demand and higher property prices. [4]

Website BSE NSE
  • Market Cap ₹ 2,237 Cr.
  • Current Price ₹ 87.1
  • High / Low ₹ 126 / 70.5
  • Stock P/E 18.0
  • Book Value ₹ 32.0
  • Dividend Yield 2.75 %
  • ROCE 17.5 %
  • ROE 14.9 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 53.1%

Cons

  • Earnings include an other income of Rs.72.8 Cr.
  • Working capital days have increased from 90.4 days to 138 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Consumer Discretionary Realty Realty Residential, Commercial Projects

Part of BSE Consumer Discretionary BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
36.10 35.65 31.15 37.94 47.51 49.08 51.10 55.97 58.22 47.89 54.04 72.28 57.73
23.32 25.54 21.53 24.79 24.14 29.63 32.72 30.26 32.21 29.31 31.52 45.23 38.18
Operating Profit 12.78 10.11 9.62 13.15 23.37 19.45 18.38 25.71 26.01 18.58 22.52 27.05 19.55
OPM % 35.40% 28.36% 30.88% 34.66% 49.19% 39.63% 35.97% 45.94% 44.68% 38.80% 41.67% 37.42% 33.86%
-8.64 2.59 47.86 2.21 1.95 1.89 65.59 4.25 2.78 3.46 64.80 2.10 2.41
Interest 0.04 0.05 0.05 0.26 0.33 0.34 0.51 0.52 0.45 0.42 0.40 0.37 0.37
Depreciation 1.61 1.74 1.77 2.57 1.38 2.41 2.59 2.59 2.66 2.70 2.72 3.34 3.25
Profit before tax 2.49 10.91 55.66 12.53 23.61 18.59 80.87 26.85 25.68 18.92 84.20 25.44 18.34
Tax % -72.29% 13.11% 7.60% 9.90% 12.41% 9.41% 5.28% 4.32% 11.10% 9.51% 10.18% 12.50% 48.04%
4.29 9.48 51.43 11.29 20.68 16.84 76.60 25.69 22.83 17.12 75.63 22.26 9.53
EPS in Rs 0.17 0.37 2.00 0.44 0.81 0.66 2.98 1.00 0.89 0.67 2.95 0.87 0.37
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
144 134 147 125 124 74 72 76 123 152 214 232
134 128 140 114 106 70 62 63 85 96 125 144
Operating Profit 10 6 7 11 18 4 11 13 38 56 90 88
OPM % 7% 5% 5% 9% 15% 5% 15% 17% 31% 37% 42% 38%
21 25 25 37 29 93 10 89 54 55 75 73
Interest 1 0 0 0 0 0 0 0 0 1 2 2
Depreciation 6 6 5 4 3 3 4 4 6 7 10 12
Profit before tax 23 25 27 44 45 94 17 97 85 103 152 147
Tax % -3% 2% -3% 5% 8% 0% 19% 12% 7% 10% 7% 15%
24 25 27 42 41 94 13 86 79 93 142 125
EPS in Rs 0.90 0.93 1.03 1.56 1.60 3.64 0.52 3.34 3.09 3.62 5.53 4.85
Dividend Payout % 17% 16% 19% 13% 12% 16% 38% 54% 71% 66% 43% 49%
Compounded Sales Growth
10 Years: 6%
5 Years: 26%
3 Years: 23%
TTM: 8%
Compounded Profit Growth
10 Years: 17%
5 Years: 67%
3 Years: 13%
TTM: -12%
Stock Price CAGR
10 Years: 11%
5 Years: -7%
3 Years: 7%
1 Year: -22%
Return on Equity
10 Years: 11%
5 Years: 12%
3 Years: 14%
Last Year: 15%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 53 53 53 53 51 51 51 51 51 51 51 51
Reserves 211 295 314 395 361 432 775 962 778 757 802 770
0 9 0 0 0 0 0 0 0 9 14 11
91 64 81 73 57 51 109 130 119 128 142 126
Total Liabilities 356 421 449 522 470 534 936 1,144 948 946 1,010 958
169 146 171 179 209 225 261 294 318 366 406 470
CWIP 2 0 0 0 0 3 6 0 0 1 0 2
Investments 35 150 189 276 205 197 581 726 503 411 414 349
149 124 89 67 55 109 88 124 127 168 190 138
Total Assets 356 421 449 522 470 534 936 1,144 948 946 1,010 958

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
22 10 52 24 22 5 -1 -22 35 25 81 117
5 -5 -47 -23 68 57 -35 23 11 23 -22 -52
-25 -5 -5 -3 -89 -6 -15 -6 -46 -48 -58 -67
Net Cash Flow 2 -0 -0 -2 1 56 -52 -5 -0 0 2 -1
Free Cash Flow 22 11 38 14 -1 -16 -44 -55 10 -31 30 41
CFO/OP 222% 172% 771% 246% 145% 187% 8% -102% 108% 42% 107% 156%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 122 76 54 74 40 44 66 72 67 42 47 48
Inventory Days 880 659 438 247 289 411 2,112 2,885 5,118 3,694 249
Days Payable 200 144 128 125 202 151 675 635 993 1,213 110
Cash Conversion Cycle 801 591 364 195 126 304 1,504 2,322 4,191 2,523 47 187
Working Capital Days 235 172 39 20 13 28 96 231 127 75 58 138
ROCE % 9% 8% 8% 10% 10% 21% 2% 10% 10% 12% 18% 17%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Investment Stake in Alembic Pharmaceuticals Ltd (APL)
%

Log in to view insights

Please log in to see hidden values.

Login
Number of Equity Shares held in Paushak Ltd
Number
API Production Capacity (Erythromycin Estolate)
MT/Month
Power Generation - Co-generation Plant
Lakh Units
Power Generation - Windmills
Lakh Units
API Production Volume (Erythromycin Estolate - Peak Month)
MT
Commercial Leasable Area (New Office Building) Pre-leased
%
Power Generation - Co-generation Plant and Windmills
Lakh Units
Project Sales Progress - The Garden
%
Project Sales Progress - The Villa
%
Project Sales Progress - Townhouse 24
%
Renewable Power Consumption (API Operations)
GJ
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88%
0.72% 0.85% 0.89% 1.07% 1.42% 1.97% 1.78% 1.65% 1.50% 1.38% 1.29% 1.25%
3.93% 3.40% 0.04% 0.04% 0.04% 0.08% 0.06% 0.05% 0.05% 0.05% 0.05% 0.05%
24.46% 24.87% 28.17% 28.02% 27.66% 27.07% 27.27% 27.41% 27.57% 27.68% 27.78% 27.81%
No. of Shareholders 81,73282,94794,01299,13098,4781,02,2491,07,4231,06,7321,07,5101,06,4701,04,1031,02,008

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings